Table 2.
HBV markers in patients treated with infliximab.
| Age | Sex | HBsAg | Anti-HBs |
Anti-HBc s/co | HBV reactivation | Entecavir | |
|---|---|---|---|---|---|---|---|
| 47 | F | Crohn | (+) | (+) | |||
| 54 | F | Crohn | (−) | (+) | (+) 6.41 | (−) | (−) |
| 47 | M | Crohn | (−) | (−) | (+) 1.62 | (+) | (+) |
| 55 | F | Crohn | (−) | (−) | (−) 0.9 | ||
| 64 | F | UC | (−) | (−) | (−) 0.09 | ||
| 19 | M | Crohn | (−) | (−) | (−) 0.05 | ||
| 34 | M | Crohn | (−) | (−) | (−) 0.11 | ||
| 52 | F | UC | (−) | (−) | (−) 0.07 | ||
| 43 | M | Crohn | (−) | (−) | (−) 0.09 | ||
| 38 | M | Behçet | (−) | (−) | (−) 0.11 | ||
| 52 | M | UC | (−) | (−) | (−) 0.08 | ||
| 18 | F | Crohn | (−) | (−) | (−) 0.05 | ||
| 42 | M | Crohn | (−) | (−) | (−) 0.15 | ||
| 41 | M | UC | (−) | (−) | (−) 0.07 | ||
| 23 | M | Crohn | (−) | (−) | (−) 0.14 |
Crohn: Crohn's disease, UC: ulcerative colitis, Behçet: Behçet's disease, M: male, F: female.